NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine
NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling significant market potential.
Moderna's mRNA Flu Vaccine Approval: A Milestone with Market Implications
Moderna's recent FDA approval for its mRNA flu vaccine marks a significant step, yet market sentiment remains cautious.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Critical Minerals in Focus: Trump's Meeting with Mining CEOs and Its Market Implications
The Trump administration's focus on critical minerals highlights opportunities for investors in Lomiko Metals and Canadi…
US Jobs Report Shock: What the -23K Non-Farm Payrolls Mean for Markets
The unexpected -23,000 non-farm payrolls in July raises questions about market stability and economic outlook.
Harrow's Strategic Acquisition of TYRVAYA: A Game-Changer for Ophthalmic Treatments
Harrow's acquisition of TYRVAYA positions it as a key player in ophthalmic treatments, offering potential revenue growth…
Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition
Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol…
Moderna's Groundbreaking mRNA Flu Vaccine Approval: A New Chapter in Vaccination
Moderna's mFLUSIVA, the first FDA-approved mRNA flu vaccine, is set to reshape the vaccination landscape and boost inves…
Harrow's Acquisition of TYRVAYA: A Game Changer for Dry Eye Treatment
Harrow Pharmaceuticals acquires TYRVAYA, the first FDA-approved nasal spray for dry eye disease, reshaping the market la…
Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors
Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its evolution beyond CO…
Bristol-Myers Squibb's Stock Reaction to AstraZeneca Merger Denial Amid Market Surge
Bristol-Myers Squibb's stock dips as AstraZeneca merger talks are denied, contrasting with a bullish Nasdaq 100 surge.
Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher
Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its supplemental NDA fi…